Muscular Dystrophy Drug Co. Beats Investor Suit Over Risks
By Sydney Price · September 16, 2026, 6:12 PM EDT
A Massachusetts federal judge denied investors another chance to rework their suit accusing Sarepta Therapeutics and its executives of misleading the market about the safety and efficacy of their muscular dystrophy...
To view the full article, register now.